News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Formycon AG initiates Phase III clinical trial for FYB206, a Keytruda biosimilar, in NSCLC patients in Eastern Europe and Southeast Asia. Study aims to compare safety and efficacy with Keytruda -
-
-
COMMUNIQUÉ DE PRESSE
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 biosimilar candidate to Stelara. Approval expected in early Q4 2024. Biosimilars boost healthcare access & reduce costs globally -
